<?xml version="1.0" encoding="UTF-8"?>
<ref id="B264-vaccines-08-00036">
 <label>264.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Waskow</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Darrasse-Jeze</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Guermonprez</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Ginhoux</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Merad</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Shengelia</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Yao</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Nussenzweig</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues</article-title>
  <source>Nat. Immunol.</source>
  <year>2008</year>
  <volume>9</volume>
  <fpage>676</fpage>
  <lpage>683</lpage>
  <pub-id pub-id-type="doi">10.1038/ni.1615</pub-id>
  <pub-id pub-id-type="pmid">18469816</pub-id>
 </element-citation>
</ref>
